Valneva (AYJ0) AI Stock Analysis
Valneva
(Frankfurt:AYJ0)
No summary available
Valneva (AYJ0) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 504.46M
- Dividend Yield
- ―
- Average Volume (3M)
- 458
- Price to Earnings (P/E)
- -2.6
- Beta (1Y)
- 0.99
- Revenue Growth
- -27.19%
- EPS Growth
- -117.39%
- Country
- Germany
- Employees
- 674
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Valneva Business Overview & Revenue Model
Company Description
Valneva SE operates as a specialized biopharmaceutical company, concentrating its efforts on developing and bringing to market preventative vaccines for infectious diseases where current medical options are insufficient. Its portfolio of commercial t...
Valneva Earnings Call Summary
The call presented meaningful operational and pipeline positives — notably a solid cash position (EUR 121.5m), active cost‑saving restructuring, regulatory progress and encouraging clinical signals for the Lyme vaccine, and commercial/partner milestones for IXCHIQ and Shigella. However, H1 2026 was marked by sizeable top‑line declines (total revenue -32.6%), margin deterioration, material one‑off manufacturing and inventory charges (EUR 9.7m cancellation fee, EUR 4.5m impairment), and a large widening of operating losses (EUR 49.9m). While management expects improvements in H2 driven by restructuring, DoD contract extension and reversal of one‑offs, the negative financial trends in H1 outweigh the positives and leave the company dependent on regulatory success for the Lyme vaccine to materially change its financial trajectory.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Valneva reiterated 2026 guidance of product sales €135–150m and total revenues €145–160m, saying H1 pacing is in line with that outlook; H1 results included product sales €64.0m (vs €91.0m a year ago) and total revenues €65.8m (vs €97.6m), cash €121.5m (up from €109.6m at FY2025) and cash used in operations €13.7m (vs €10.9m), an operating loss of €49.9m (vs €16.8m) and an adjusted EBITDA loss of €40.1m (vs €6.0m). Cost of goods and services were €59.5m (vs €47.2m), including a €9.7m cancellation‑fee provision and a €4.5m inventory impairment; IXIARO sales €44.0m (vs €54.7m) with 56.4% gross margin (vs 65.5%), DUKORAL €14.7m (vs €17.4m) with 24.7% margin (vs 52.9%), IXCHIQ €4.4m (vs €7.5m) and third‑party products €1.0m (vs €11.4m). Operating expenses showed cuts—R&D €30.2m (vs €32.4m), marketing & distribution €13.5m (vs €20.3m), G&A €15.4m (vs €19.0m)—with a one‑time restructuring cost of €3.2m; management expects product‑related gross margin, P&L and cash flow to improve in H2 after non‑recurring effects, anticipates a new U.S. DoD IXIARO contract in the coming months, and says the company could become financially self‑sustainable starting in 2026 pending regulatory approval and Pfizer commercialization of the Lyme vaccine.
Valneva Risk Analysis
Valneva disclosed 86 risk factors in its most recent earnings report. Valneva reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
1 New RiskValneva Peers Comparison
Overall Rating
ABUS61Neutral
URGN60Neutral
SANA50Neutral
TSHA49Neutral
IVA46Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ABUS | 61Neutral | $834.03M | 5.06 | 90.98% | ― | 1078.78% | ― |
| URGN | 60Neutral | $1.60B | -17.35 | 81.78% | ― | 100.27% | 39.90% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| SANA | 50Neutral | $769.36M | -3.16 | -134.49% | ― | ― | 28.46% |
| TSHA | 49Neutral | $1.35B | -9.46 | -56.19% | ― | -32.27% | -21.09% |
| IVA | 46Neutral | $850.40M | -6.08 | -1625.48% | ― | -99.61% | 66.37% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:AYJ0 | Valneva Se | 4.68 | -2.87 | -38.01% | |
| ABUS | Arbutus Biopharma | 4.00 | -0.61 | -13.23% | |
| URGN | Urogen Pharma | 34.36 | 15.05 | 77.94% | |
| IVA | Inventiva SA ADR | 3.83 | -0.27 | -6.59% | |
| TSHA | Taysha Gene Therapies, Inc. | 4.00 | -0.03 | -0.74% | |
| SANA | Sana Biotechnology, Inc. | 2.40 | -1.68 | -41.18% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.